Next, we revealed the regulatory mechanisms of ELFN1‐AS1, miR‐185‐5p and BCL‐2 in DLBCL cells and discovered that ELFN1‐AS1 upregulated BCL‐2 by sponging miR‐185‐5p, which could be a key mechanism and therapeutic target for DLBCL treatment. Here, ELFN1 is linked to diffuse large B-cell lymphoma.